MiNK Therapeutics CEO Jennifer Buell

In wan­ing Covid mar­ket, MiNK un­veils da­ta on nat­ur­al killer T cell ther­a­py for ARDS, pend­ing con­tract with DARPA

In an SITC poster, Agenus’ spin­out MiNK Ther­a­peu­tics dropped the re­sults of a Phase I/II study of its lead can­di­date, made from rare im­mune cells …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA